Kiniksa Pharmaceuticals International, plc 8-K

What Happened
Kiniksa Pharmaceuticals International, plc (KNSA) filed an 8‑K reporting that on May 21, 2026 it entered into a Deed of Waiver with Baker Bros. Advisors LP, on behalf of Baker Brothers Life Sciences, L.P. and 667, L.P. The Shareholders waived their right to convert Class A1 or Class B1 ordinary shares into Class A or Class B ordinary shares if such conversion would cause them to beneficially own more than 49.9% of the Company’s outstanding voting rights.

Key Details

• Deed date: May 21, 2026; 8‑K filed May 26, 2026.
• Parties: Kiniksa and Baker Bros. Advisors LP (representing Baker Brothers Life Sciences, L.P. and 667, L.P.).
• Restriction: Shareholders waived Conversion Rights that would result in >49.9% of voting power.
• Amendment threshold: Deed may only be amended, waived or terminated by a vote of at least 75% of the Company’s outstanding ordinary shares, except no vote is required to (a) add more shareholders to the Deed or (b) add additional restrictions on the Shareholders’ Conversion Rights.

Why It Matters
This agreement limits the ability of the named Baker Bros. entities to increase their voting control through conversion of certain share classes, keeping any single holder’s voting power below a 50% threshold. For investors, that affects potential shifts in corporate control and voting outcomes on governance matters. The high amendment vote requirement (75%) means changes to the Deed would need broad shareholder support, although the Deed allows adding parties or adding restrictions without a shareholder vote.